
Scholarly Expertise: Traumatic Brain Injury (TBI)


Jesse Fann
Personal Statement
I am a consultation-liaison psychiatrist and health services researcher in the Department of Psychiatry and Behavioral Sciences and Adjunct Professor in the Departments of Rehabilitation Medicine and Epidemiology. I am also Medical Director of the Department of Psychosocial Oncology at Fred Hutchinson Cancer Center. My research interests are in psychiatric epidemiology, health services research, psychiatric oncology, and neuropsychiatry. In my clinical practice, I use a comprehensive, multifaceted approach that may include medications or counseling to help patients achieve their goals. My primary interest is helping people who are coping with medical illness. I am particularly interested in developing better approaches to delivering person-centered psychiatric care to these populations.
Carol Rockhill
Personal Statement
I am a child and adolescent psychiatrist with experience in delivering guideline-based care for child and adolescent psychiatric disorders. I am the Medical Director of the Outpatient Psychiatry Clinics at Seattle Children’s, and have experience with training of staff to deliver guideline-based care. I also have health services training, including having obtained a Master of Public Health (MPH) in Health Services and participation in a Primary Care-Psychiatry Research Fellowship funded by the National Institutes of Health.
My clinical work includes treatment of outpatients and inpatients with a variety of mental health needs, and I provide telepsychiatry in our outpatient clinics. I have experience with collaboration with primary care providers to deliver care to pediatric patients, including serving as a consulting psychiatrist on the Partnership Access Line, which provides psychiatric consultation regarding mental health assessment and treatment to pediatricians and other primary care physicians throughout the state of Washington. I have expertise in the treatment of common mental health problems in a pediatric population.
My research has focused on mental health care for common psychiatric illnesses including depression and ADHD, and has included utilization of collaborative models of care and testing of interventions for youth with psychiatric diagnoses. I have been a co-investigator, with R01 PI Kathleen Myers, MD, for a study of guideline-based care provided by telepsychiatry for youth in rural communities with a diagnosis of Attention Deficit Hyperactivity Disorder.

Garth Terry
Personal Statement
My research interests cover two main areas:
1) development and use of novel radioligands for positron emission tomography (PET) in CNS disorders
2) cannabinoid pharmacology, and cannabis use disorder and comorbid neuropsychiatric disorders
My VA Career Development Award (VA equivalent of an NIH K-award) focuses on the translational development of imaging neuroinflammation with PET following repetitive blast mild traumatic brain injury (mTBI). In collaboration with David Cook’s lab, imaging neuroinflammation in a mouse model of repetitive mTBI provides an opportunity to compare imaging outcomes directly with histopathology in brain tissue, which is not possible in humans. In collaboration with Elaine Peskind, imaging neuroinflammation in Veterans with mTBI and persistent post-concussive symptoms provides neuroanatomical specificity to ongoing neuroinflammation, which to date has been informed using cerebrospinal fluid and serum biomarkers. To accomplish this, my laboratory evaluates and develops established and novel PET radioligands for biomarkers of neuroinflammation. Additionally, I am interested in developing novel radioligands for druggable targets for which there are no current, suitable radioligands available. I have several ongoing collaborations with other investigators at UW and VA in which I provide support with PET imaging.
As a clinician and researcher, I am interested in how patients use cannabis for perceived therapeutic effect, and the risks and adverse outcomes resulting from substantial or chronic cannabis use. These clinical patterns can now be placed into context with a better understanding of the endocannabinoid system (ECS), which provide opportunity for more selective and safer therapeutic drug development. Due in part to the recentness of discovery of the ECS, one of my goals is to educate clinical providers on the preclinical and evidenced based research conducted to date on cannabis use and the ECS so they are better informed when discussing cannabis use with patients, and better prepared for understanding mechanisms of anticipated ECS-based medications currently under development. A second goal is to conduct research on cannabis use disorder and comorbid conditions, and identification of therapies that might better address a patient’s desired outcome from cannabis use, thereby reducing the likelihood of its associated risks.
Elaine Peskind
Personal Statement
I am Co-Director of the VA VISN 20 (Northwest Network) Mental Illness Research, Education, and Clinical Center (MIRECC). I am also the Friends of Alzheimer’s Research Professor of Psychiatry and Behavioral Sciences at the University of Washington (UW) School of Medicine and am Associate Director of the UW Alzheimer’s Disease Research Center. My research over the past 30 years has addressed cognitive and behavioral problems and cerebrospinal fluid (CSF) biomarkers in neurodegenerative dementing disorders such as Alzheimer’s disease. More recently, my research has focused on combat trauma posttraumatic stress disorder and the clinical phenomenology as well as neuroimaging and CSF biomarkers of neurodegeneration in combat blast concussion mild traumatic brain injury and in Gulf War Veterans Illness. I continue to conduct single site as well as multi-site large scale studies of CSF biomarkers and pharmacological treatment trials for behavioral disorders and traumatic brain injury.
Summary of my research program:
Blast Concussion Mild Traumatic Brain Injury (mTBI)
Strategies: multimodal neuroimaging: structural and functional magnetic resonance imaging (diffusion tensor imaging [DTI], DTI tractography, macromolecular proton fraction mapping, resting state and task-based functional MRI; susceptibility-weighted imaging, FDG-positron emission tomography [PET]; cerebrospinal fluid and plasma biomarkers; genetic risk factors; clinical, neurocognitive and behavioral assessments,
Gulf War Veterans Illness (GWVI)
Strategies: multimodal neuroimaging and CSF and plasma biomarkers as described above, epigenetics, pain sensitivity testing and ability to activate endogenous opioid systems, and functional activity of paraoxonase I, the enzyme that metabolizes organophosphate insecticides.
Cerebrospinal Fluid and Plasma Biomarkers of Neurodegeneration Strategies: Bead-based multiplex assays using Luminex and Meso-Scale platforms, Quanterix ultra-sensitive platform, and broad-scale mass spectrometry for measurement of proteins, circulating RNAs, microRNAs in collaboration with VA/UW and Institute for Systems Biology investigators.
Pharmacologic Treatment of Disruptive Agitation in Alzheimer’s Disease (AD)
Strategies: Alzheimer’s Disease Cooperative Study multi-center randomized placebo-controlled trial of the alpha-1 adrenoreceptor antagonist, prazosin, for treatment of disruptive agitation in AD.

Erik S. Carlson
Personal Statement
I am a basic neuroscientist, a board-certified practicing psychiatrist, and an Assistant Professor of Psychiatry and Behavioral Sciences at the University of Washington Medical School. The goal of my research is to investigate the neural circuitry of cognitive, emotional and memory processing, particularly as it relates to the cerebellum, and illnesses affecting cerebellum including cognitive disorders, PTSD, TBI and dementia through the implementation of techniques in mouse behavioral genetics. In my clinical practice, I primarily see veterans with PTSD, mild cognitive impairment, and various forms of dementia in an outpatient clinic at the VAMC Puget Sound Geriatric Research, Education, and Clinical Center (GRECC) in Seattle. I have over 15 years of experience in basic science research with most of that time dedicated to the use of mouse models of neuropsychiatric disorders. Throughout my training prior to and during graduate school, I gained background in many contemporary molecular and biochemical lab techniques, such as molecular cloning, protein biochemistry, protein crystal production, fluorometric measurement of protein kinetics, in vivo NMR spectroscopy, gene targeting, microarray genomics, immunohistochemistry, and mammalian cell culture. I have a foundation in mouse genetics, neural development, and behavior which I developed in Michael Georgieff’s lab by investigating the role of iron in developing pyramidal neurons of the mouse hippocampus. During graduate training, I also received cross-training in child psychological development. In graduate school, I developed two mouse models of nonanemic neuron specific iron deficiency: 1) a conditional knockout of the Slc11a2 gene, encoding the iron transporter DMT-1 in forebrain neurons, including hippocampal pyramidal neurons, and 2) a transgenic mouse with a reversibly inducible dominant negative (nonfunctional) form of the transferrin receptor expressed only in hippocampal pyramidal neurons. I utilized and implemented different versions of the Morris Water Maze to study learning deficits in these mouse models of perinatal brain iron deficiency, a condition that is often a consequence of diabetes during pregnancy. During my residency training, I expanded my knowledge of neuropsychiatric disorders by directly evaluating and treating patients with neuropsychiatric disorders including PTSD, schizophrenia, Alzheimer’s disease, autism, major depression, substance abuse disorders, and personality disorders. I learned numerous pharmacological, neuromodulatory, and psychotherapeutic interventions and participated in the internally funded Neuroscience Research Track. I then received a NIMH career development award (K08) mentored by Larry Zweifel, Ph.D. In that position, I investigated interactions between catecholamines and the cerebellum in decision making, emotional and cognitive processing. In the 5 years I was in Dr. Zweifel’s lab, I learned many additional new techniques including use of viral vectors, in vivo electrophysiology, and several operant- and threat-based behaviors, and moved forward in my goal of becoming a physician scientist isolating important circuits underlying etiology of specific domains of behavioral function. This work culminated in my receiving an RO1 independent investigator award, without any gap in funding. My current research utilizes mouse behavior, in vivo electrophysiological recordings, gene targeting, viral vectors, translational profiling, chemo- and optogenetic tools, site-specific intracranial viral vector injection, and protein chemistry. I am now forging my path as an independent investigator, and my primary goal is to understand cerebellar circuits as they relate to psychiatric and neurodegenerative illnesses and utilize this knowledge to inform and improve current and novel psychiatric illnesses, primarily in cognitive and emotional domains. As such, I am pursuing a multidisciplinary approach combining genetic, electrophysiological, pharmacological, and behavioral techniques.
Christopher Varley
Personal Statement
My primary interest is Graduate Medical Education and Faculty Development in Child and Adolescent Psychiatry. I was the program director for the Child and Adolescent Psychiatry residency at the UWSOM for 32 years. I am now the Director of Education and Faculty Development in the Division of Child and Adolescent Psychiatry. My clinical interests are in pediatric psychopharmacology, particularly re ADHD.
Taylor Black
Personal Statement
I came to the UW to train in psychosomatic medicine and to work in a complex comorbid population as a clinician and a teacher. Most medical and surgical patients served at Harborview will have psychosocial needs; often these are as critical to their recovery and health as somatic health problems. Working across disciplines is challenging but also clinically valuable, intellectually stimulating, and exciting to our trainees when we can address care in a more integrated and holistic manner. I like to focus my academic work on defining what the needs of Harborview’s clinical population are, and how our busy psychiatric consultation services can be best utilized to promote the health of our patients and our institutions.

Ty Lostutter
Personal Statement
I am a licensed clinical psychologist in Washington State. I am the Director of the University of Washington School of Medicine’s Psychology Internship Program which is accredited by the American Psychological Association’s Office of Program Consultation and Accreditation. And, I conduct research on health and risk behaviors across the lifespan. Specifically, I have conducted research in the areas of college student alcohol use, young adult gambling behavior, and co-morbidity of substance use and mental health/risk behaviors (i.e. risky sexual behaviors). I have extensive experience working with college students/young adults, military/veteran, and minority/diverse populations. I am also interested in mental health issues including depression, anxiety, and PTSD. I maintain an active clinical practice in the areas of mental health issues with patients diagnosed with hematological and oncological illness and have clinical responsibilities at the Fred Hutchinson Cancer Center. I also provide clinical supervision for psychology residents and psychology practicum students at Fred Hutchinson Cancer Center as well. Overall, my professional aspirations are to improve the public health through empirically-supported psychological interventions and providing mentorship to diverse trainees to expand the reach of psychology.